CSF biomarker profile and diagnostic value in vascular dementia

Paraskevas, GP; Kapaki, E; Papageorgiou, SG; Kalfakis, N; Andreadou, E; Zalonis, I; Vassilopoulos, D

dc.contributor.author	Paraskevas, GP	en
dc.contributor.author	Kapaki, E	en
dc.contributor.author	Papageorgiou, SG	en
dc.contributor.author	Kalfakis, N	en
dc.contributor.author	Andreadou, E	en
dc.contributor.author	Zalonis, I	en
dc.contributor.author	Vassilopoulos, D	en
dc.date.accessioned	2014-03-01T01:58:52Z
dc.date.available	2014-03-01T01:58:52Z
dc.date.issued	2009	en
dc.identifier.issn	1351-5101	en
dc.identifier.uri	https://dspace.lib.ntua.gr/xmlui/handle/123456789/28761
dc.subject	Alzheimer's disease	en
dc.subject	cerebrospinal fluid	en
dc.subject	phospho-tau	en
dc.subject	tau protein	en
dc.subject	vascular dementia	en
dc.subject	beta-amyloid	en
dc.subject.classification	Clinical Neurology	en
dc.subject.classification	Neurosciences	en
dc.subject.other	CEREBROSPINAL-FLUID TAU	en
dc.subject.other	BETA-AMYLOID 1-42	en
dc.subject.other	ALZHEIMERS-DISEASE	en
dc.subject.other	CLINICAL-CRITERIA	en
dc.subject.other	PROTEIN	en
dc.subject.other	MARKERS	en
dc.subject.other	MULTICENTER	en
dc.subject.other	POPULATION	en
dc.subject.other	PATHOLOGY	en
dc.subject.other	DISORDER	en
dc.title	CSF biomarker profile and diagnostic value in vascular dementia	en
heal.type	journalArticle	en
heal.language	English	en
heal.publicationDate	2009	en
heal.abstract	The differential diagnosis between vascular dementia (VD) and Alzheimer's disease (AD) or mixed dementia (MD) is not always easy in clinical practice. The purpose of the present study was to evaluate the cerebrospinal fluid (CSF) biomarkers tau protein in its total (tau(T)) or hyperphosphorylated at threonin-181(tau(P-181)) form and beta amyloid peptide 1-42 (A beta 42) alone and their combinations to investigate their diagnostic value in the discrimination between VD and AD or MD. The above CSF biomarkers were determined in duplicate and blind to the clinical diagnosis by double sandwich, enzyme-linked immunosorbent assay (ELISA) commercial kits (Innogenetics, Gent, Belgium) in 92 AD patients, 23 VD patients, 17 patients with MD and 68 controls. Alzheimer's disease and MD showed increased levels of tau(T), tau(P) and reduced levels of A beta 42 as compared with the controls. The best discrimination between VD and AD or MD was achieved by the combination of all three biomarkers, correctly classifying >= 85% of patients, either in the form of a discriminant function or in the form of the tau(T) x tau(P-181)/A beta 42 formula. Cerebrospinal fluid biomarkers may be a useful adjunct for the discrimination between AD/ MD and VD in every day clinical practice.	en
heal.publisher	BLACKWELL PUBLISHING	en
heal.journalName	EUROPEAN JOURNAL OF NEUROLOGY	en
dc.identifier.isi	ISI:000262468900019	en
dc.identifier.volume	16	en
dc.identifier.issue	2	en
dc.identifier.spage	205	en
dc.identifier.epage	211	en